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Summary and Implications 
 Replicon particles (RPs) expressing the GP5 and Matrix 
structural proteins of Porcine Reproductive and Respiratory 
Syndrome Virus (PRRSV) were created and compared to 
inactivated PRRSV in a challenge study.  Pigs that received 
the RP vaccine had lower live virus titers and showed lower 
IDEXX ELISA values following challenge when compared 
to other groups. 
 These results show that the RP vaccine provided partial 
protection against challenge with virulent PRRSV.  Also, 
the RP vaccine allows for differentiation between 
vaccinated and naturally infected animals. 
 
Introduction 
 Porcine reproductive and respiratory syndrome (PRRS) 
is one of the economically significant diseases facing the 
swine industry. New strategies for preventing and 
eliminating the disease are needed.  In addition to providing 
protection, new vaccines should allow for enhanced 
diagnostic methods that will aid attempts to eradicate the 
disease locally and nationally. 
 
Materials and Methods 
 We created RP vectors expressing GP5 and Matrix 
proteins of PRRSV. Pigs receiving these RP vaccines were 
compared to groups receiving inactivated PRRSV, a 
placebo, and a group of strict negative control pigs. Forty 
crossbred pigs were obtained at three weeks of age and 
randomized into groups of ten. Pigs were immunized on 
Day 0 and Day 28 of the study. Serum samples were 
collected at seven day intervals during the course of the 
study. All pigs except strict negative control pigs were 
challenged intranasally on Day 49 with 2 ml of 1x105 
TCID50/ml of virulent PRRSV strain HLV349. This strain is 
homologous to the GP5 and Matrix genes used to construct 
the RP. Pigs were euthanized 21 days after challenge. A 
necropsy was performed, and tissues were collected for 
laboratory testing, including: quantitative gross lung lesion 
scoring, histopathology, IDEXX ELISA, virus titration, and 
virus neutralization. 
 
Results and Discussion 
 Following challenge, mean IDEXX ELISA S/P ratios 
were significantly lower in pigs that received RP vaccine 
compared to other challenged groups. The RP vaccinated 
pigs had significantly lower serum live virus titers at 7 days 
post challenge compared to placebo- and inactivated 
PRRSV-vaccinated pigs. No live virus was detected in any 
pigs at 14 or 21 days post challenge. The strict negative pigs 
had no detectable live virus at any time post-challenge. 
Histopathology of tissues showed no differences between 
groups at necropsy. These results indicate that RP vaccine 
provided partial protection from challenge with virulent 
PRRSV. The absence of anti-nucleocapsid seroconversion 
in RP vaccinated pigs prior to challenge provides a way to 
serologically differentiate between naturally infected and 
vaccinated animals. 
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